Molecure SA engages in the discovery and development of small molecules for the treatment of unmet medical needs. It offers a platform of distinct small molecule programs targeting chitinases and chitinase-like-proteins, with potential utility in diverse inflammatory and fibrotic diseases. The company was founded by Stanislaw Wieslaw Pikul and Adam Golebiowski on March 12, 2012 and is headquartered in Warsaw, Poland.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company